公开(公告)号：US20230287120A1

公开(公告)日：2023-09-14

申请号：US18308143

申请日：2023-04-27

Applicant: ALLOGENE THERAPEUTICS, INC. ,  PFIZER INC.

Inventor： Yi ZHANG ,  Thomas John VAN BLARCOM ,  Siler PANOWSKI ,  Silvia K. TACHEVA-GRIGOROVA ,  Barbra Johnson SASU

IPC: C07K16/28 ,  A61P35/00 ,  C12N15/63

CPC classification number: C07K16/2809 ,  A61P35/00 ,  C07K16/2887 ,  C12N15/63 ,  A61K2039/505

Abstract: Provided herein are DLL3 binding agents and chimeric antigen receptors (CARs) comprising a DLL3 binding molecule that specifically binds to DLL3; and immune cells comprising these DLL3-specific CARs, e.g., CAR-T cells. Also provided are methods of making and using DLL3-specific CARs, and immune cells comprising DLL3-specific CARs.

公开(公告)号：US20230041456A1

公开(公告)日：2023-02-09

申请号：US17843616

申请日：2022-06-17

Applicant: Pfizer Inc.

Inventor： Surabhi SRIVATSA SRINIVASAN ,  Niranjana NAGARAJAN ,  Siler PANOWSKI ,  Yoon PARK ,  Tao SAI ,  Barbra SASU ,  Thomas VAN BLARCOM ,  Mathilde DUSSEAUX ,  Roman GALETTO

IPC: C07K16/28 ,  A61K39/00 ,  C07K14/725 ,  A61P35/02 ,  A61P35/04

Abstract: The disclosure provides CARs (CARs) that specifically bind to CD70. The disclosure further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The disclosure further relates to therapeutic methods for use of these CARs and engineered immune cells comprising these CARs for the treatment of a condition associated with malignant cells expressing CD70 (e.g., cancer).

公开(公告)号：US20240216430A1

公开(公告)日：2024-07-04

申请号：US18521196

申请日：2023-11-28

Applicant: ALLOGENE THERAPEUTICS, INC. ,  PFIZER INC.

Inventor： Zhe LI ,  Siler PANOWSKI ,  Barbra Johnson SASU ,  Bryan A. SMITH ,  Thomas John VAN BLARCOM ,  Tao SAI ,  Guoyun ZHU

IPC: A61K35/17 ,  A61K39/00 ,  C07K16/28

CPC classification number: A61K35/17 ,  A61K39/4611 ,  A61K39/4631 ,  A61K39/464438 ,  C07K16/2875 ,  A61K2039/505 ,  A61K2239/13 ,  A61K2239/17 ,  A61K2239/21 ,  A61K2239/22 ,  A61K2239/23 ,  A61K2239/29 ,  A61K2239/31 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/622

Abstract: Provided herein are Claudin 18.2 binding agents and chimeric antigen receptors (CARs) comprising a Claudin 18.2 binding molecule that specifically binds to Claudin 18.2; and immune cells comprising these Claudin 18.2-specific CARs, e.g., CAR-T cells. Also provided are methods of making and using Claudin 18.2-specific CARs and Claudin 18.2 binding agents, and immune cells comprising Claudin 18.2-specific CARs.

公开(公告)号：US20220227832A1

公开(公告)日：2022-07-21

申请号：US17557654

申请日：2021-12-21

Applicant: ALLOGENE THERAPEUTICS, INC. ,  PFIZER INC.

Inventor： Shanshan LANG ,  Thomas John VAN BLARCOM ,  Michael Thomas BETHUNE ,  Siler PANOWSKI ,  Nguyen TAN ,  Yi ZHANG ,  Barbra Johnson SASU ,  Zhe LI

IPC: C07K14/725 ,  C07K14/705 ,  C12N15/79 ,  C07K19/00

Abstract: A reversibly gated effector polypeptide e.g. a chimeric antigen receptor (protease-activating CD45-gate CAR) comprising an extracellular CD45 recruiting domain, a protease-cleavable linker, and a polypeptide comprising an extracellular ligand binding domain, a transmembrane domain, and an intracellular domain. Nucleic acids including vectors and expression vectors that encode the protease-activating CD45-gate CAR and cells including immune cells such as T cells that comprise and express the nucleic acids. Methods of treatment of various conditions including various forms of cancer comprising administering the cells including CAR T cell therapy. In some embodiments, the CD45 gate at least partially inhibits activation of the protease-activating CD45-gate CAR when the protease-activating CD45-gate CAR binds antigen. The inhibition is at least partially diminished, relieved and/or eliminated when the protease-activating CD45-gate CAR is exposed to a protease that can cleave the linker.

公开(公告)号：US20250011446A1

公开(公告)日：2025-01-09

申请号：US18639749

申请日：2024-04-18

Applicant: Pfizer Inc.

Inventor： Siler PANOWSKI ,  Tao SAI ,  Barbra Johnson SASU ,  Surabhi SRIVATSA SRINIVASAN ,  Thomas John VAN BLARCOM

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00

Abstract: The present invention provides antibodies that specifically bind to CD70 (Cluster of Differentiation 70). The invention further provides bispecific antibodies that bind to CD70 and another antigen (e.g., CD3). The invention further relates to antibody encoding nucleic acids, and methods of obtaining such antibodies (monospecific and bispecific). The invention further relates to therapeutic methods for use of these antibodies for the treatment of CD70-mediated pathologies, including cancer.

公开(公告)号：US20210107979A1

公开(公告)日：2021-04-15

申请号：US16802822

申请日：2020-02-27

Applicant: ALLOGENE THERAPEUTICS, INC. ,  PFIZER INC.

Inventor： Yi ZHANG ,  Thomas John VAN BLARCOM ,  Siler PANOWSKI ,  Silvia K. TACHEVA-GRIGOROVA ,  Barbra Johnson SASU

IPC: C07K16/28 ,  C12N15/63 ,  A61P35/00

Abstract: Provided herein are DLL3 binding agents and chimeric antigen receptors (CARs) comprising a DLL3 binding molecule that specifically binds to DLL3; and immune cells comprising these DLL3-specific CARs, e.g., CAR-T cells. Also provided are methods of making and using DLL3-specific CARs, and immune cells comprising DLL3-specific CARs.